Skip to content

Clinical trials

Terminated Leukemia, Monocytic, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Monocytic, Acute Status: Terminated Clear all

28 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20043
20052
20061
20071
20082
20091
20103
20112
20122
20131
20145
20151
20201
20211

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated28

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)6
Fred Hutchinson Cancer Center5
Roswell Park Cancer Institute4
Rutgers, The State University of New Jersey2
Alliance for Clinical Trials in Oncology1
Bruno C. Medeiros1
H. Lee Moffitt Cancer Center and Research Institute1
Masonic Cancer Center, University of Minnesota1
Northwestern University1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Monocytic, Acute28
Leukemia, Myeloid, Acute27
Leukemia, Erythroblastic, Acute25
Congenital Abnormalities24
Leukemia, Megakaryoblastic, Acute24
Leukemia, Myelomonocytic, Acute24
Leukemia8
Leukemia, Basophilic, Acute7
Leukemia, Eosinophilic, Acute7
Blast Crisis5

Trials

Showing 51 to 28 of 28. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.